Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Olema Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
OLMA
Nasdaq
8731
https://olema.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Olema Pharmaceuticals Inc
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
- Apr 8th, 2024 8:30 pm
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
- Apr 5th, 2024 4:16 am
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 2nd, 2024 8:29 pm
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
- Mar 11th, 2024 8:03 pm
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
- Mar 6th, 2024 12:03 pm
Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
- Mar 4th, 2024 10:05 am
Olema Oncology to Participate in Upcoming Investor Conferences
- Feb 6th, 2024 12:01 pm
15 Small-Cap Stocks with High Potential
- Jan 22nd, 2024 3:54 pm
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
- Jan 8th, 2024 1:12 pm
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 9:01 pm
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
- Dec 5th, 2023 5:27 pm
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
- Nov 28th, 2023 10:10 pm
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
- Nov 27th, 2023 5:54 pm
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
- Nov 22nd, 2023 2:00 pm
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 7th, 2023 9:02 pm
Olema Oncology to Participate in Upcoming Investor Conferences in November
- Nov 1st, 2023 8:27 pm
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
- Oct 30th, 2023 12:50 pm
Olema Pharmaceuticals, Inc.'s (NASDAQ:OLMA) high hedge funds ownership speaks for itself as stock continues to impress, up 24% over last week
- Oct 28th, 2023 1:42 pm
12 Best Performing NASDAQ Stocks in 2023
- Oct 26th, 2023 2:33 pm
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
- Oct 22nd, 2023 6:55 am
Scroll